Adage Capital Amends EyePoint Pharma Stake as of Dec 31, 2023

TL;DR

**Adage Capital updated its EyePoint Pharma stake, watch for details on their new position.**

AI Summary

Adage Capital Partners, L.P. has updated its ownership stake in EyePoint Pharmaceuticals, Inc. (EYPT) as of December 31, 2023, filing an amended Schedule 13G/A. This filing indicates a change in their beneficial ownership, which is important for investors because large institutional holdings can influence stock price and signal confidence (or lack thereof) in the company's future prospects. While the exact percentage change isn't specified in the provided text, the amendment suggests a re-evaluation of their position in the company's common stock, par value $0.001 per share.

Why It Matters

Changes in significant institutional ownership can impact investor sentiment and stock liquidity, potentially signaling a shift in how large funds view EyePoint Pharmaceuticals' future.

Risk Assessment

Risk Level: low — This filing is a routine update on institutional ownership and does not inherently signal high risk, though the underlying change in ownership could be positive or negative.

Analyst Insight

Investors should monitor subsequent filings or news from Adage Capital Partners, L.P. to understand the specific changes in their ownership percentage and evaluate if this signals a bullish or bearish outlook on EyePoint Pharmaceuticals, Inc.

Key Numbers

• $0.001 — Par Value per Share (The par value of EyePoint Pharmaceuticals, Inc. common stock.)
• 30233G209 — CUSIP Number (The unique identification number for EyePoint Pharmaceuticals, Inc. common stock.)

Key Players & Entities

• EyePoint Pharmaceuticals, Inc. (company) — the subject company whose securities are being reported
• Adage Capital Partners, L.P. (company) — the reporting person filing the SC 13G/A
• Adage Capital Partners GP, L.L.C. (company) — the general partner of the reporting person
• $0.001 (dollar_amount) — par value per share of EyePoint Pharmaceuticals' common stock
• December 31, 2023 (date) — the date of the event requiring the filing of this statement

Forward-Looking Statements

• Adage Capital Partners, L.P. will continue to hold a significant stake in EyePoint Pharmaceuticals, Inc. (Adage Capital Partners, L.P.) — medium confidence, target: Q1 2024

FAQ

Key Financial Figures

• $0.001 — me of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securitie

Filing Documents

• p24-0429sc13ga.htm (SC 13G/A) — 91KB
• 0000902664-24-001182.txt ( ) — 93KB

(a)

Item 1(a). NAME OF ISSUER The name of the issuer is EyePoint Pharmaceuticals, Inc. (the “ Company ”).

(b)

Item 1(b). ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES The Company’s principal executive offices are located at 480 Pleasant Street, Watertown, MA 02472.

(a)

Item 2(a). NAME OF PERSON FILING This statement is filed by: (i) Adage Capital Partners, L.P., a Delaware limited partnership (“ ACP ”) with respect to the Common Stock directly owned by it; (ii) Adage Capital Partners GP, L.L.C., a limited liability company organized under the laws of the State of Delaware (“ ACPGP ”), as general partner of ACP with respect to the Common Stock directly owned by ACP; (iii) Adage Capital Management, L.P., a Delaware limited partnership (“ ACM ”), as the investment manager of ACP, with respect to the Common Stock directly owned by ACP; (iv) Robert Atchinson (“ Mr. Atchinson ”), as (1) managing member of Adage Capital Advisors, L.L.C., a limited liability company organized under the laws of the State of Delaware (“ ACA ”), managing member of ACPGP and (2) managing member of Adage Capital Partners LLC, a Delaware limited liability company (“ ACPLLC ”), general partner of ACM, with respect to the Common Stock directly owned by ACP; and (v) Phillip Gross (“ Mr. Gross ”), as (1) managing member of ACA, managing member of ACPGP and (2) managing member of ACPLLC, general partner of ACM, with respect to the Common Stock directly owned by ACP. The foregoing persons are hereinafter sometimes collectively referred to as the “ Reporting Persons .” Any disclosures herein with respect to persons other than the Reporting Persons are made on information and belief after making inquiry to the appropriate party. The filing of this statement should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of the securities reported herein.

(b)

Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE The address of the business office of each of the Reporting Persons is 200 Clarendon Street, 52nd Floor, Boston, Massachusetts 02116.

(c)

Item 2(c). CITIZENSHIP ACP and ACM are limited partnerships organized under the laws of the State of Delaware. ACPGP is a limited liability company organized under the laws of the State of Delaware. Messrs. Gross and Atchinson are citizens of the United States.

(d)

Item 2(d). TITLE OF CLASS OF SECURITIES Common Stock, par value $0.001 per share (the “ Common Stock ”).

(e)

Item 2(e). CUSIP NUMBER 30233G209 CUSIP No. 30233G209 13G/A Page 8 of 10 Pages Item 3. IF THIS STATEMENT IS FILED PURSUANT TO Rules 13d-1(b), OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A: (a) Broker or dealer registered under Section 15 of the Act; (b) Bank as defined in Section 3(a)(6) of the Act; (c) Insurance company as defined in Section 3(a)(19) of the Act; (d) Investment company registered under Section 8 of the Investment Company Act of 1940; (e) An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E); (f) An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F); (g) A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G); (h) A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act; (i) A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act; (j) A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J); (k) Group, in accordance with Rule 13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution: Not applicable. Item 4. The information required by Items 4(a) – (c) is set forth in Rows (5) – (11) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person. The percentage set forth in this Schedule 13G is calculated based upon 48,838,843 shares of Common Stock reported to be outstanding in the Company’s Prospectus Supplement filed pursuant to Rule 424(b)(5) filed with the Securities and Exchange Commission on December 7, 2023, and the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on December 8, 2023, after giving effect to the completion of the offering and the full exercise of the underwriter’ o

SIGNATURES

SIGNATURES After reasonable inquiry and to the best of his or its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct. DATE: February 7, 2024 ADAGE CAPITAL PARTNERS, L.P. By: Adage Capital Partners GP, L.L.C., its general partner By: Adage Capital Advisors, L.L.C., its managing member /s/ Robert Atchinson Name: Robert Atchinson Title: Managing Member ADAGE CAPITAL PARTNERS GP, L.L.C. By: Adage Capital Advisors, L.L.C., its managing member /s/ Robert Atchinson Name: Robert Atchinson Title: Managing Member ADAGE CAPITAL MANAGEMENT, L.P. By: Adage Capital Partners LLC, its general partner /s/ Robert Atchinson Name: Robert Atchinson Title: Managing Member /s/ Robert Atchinson ROBERT ATCHINSON, individually /s/ Phillip Gross PHILLIP GROSS, individually

View Full Filing

View this SC 13G/A filing on SEC EDGAR